Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
0.9126
+0.0096 (1.06%)
May 26, 2026, 4:00 PM EDT - Market closed
Jasper Therapeutics Stock Forecast
JSPR's stock price has decreased by -80.87% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 7 analysts polled by S&P Global, Jasper Therapeutics stock has a consensus rating of "Buy" and an average price target of $7.50. The average 1-year stock price forecast is 721.83% higher than the current stock price, while the lowest is $1.50 (+64.37%) and the highest is $20 (+2,091.54%).
Price Target: $7.50 (+721.83%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Jasper Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 3 | 3 | 3 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 3 | 3 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $4 → $3 | Hold | Maintains | $4 → $3 | +228.73% | May 15, 2026 |
| TD Cowen | TD Cowen | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | May 15, 2026 |
| William Blair | William Blair | Hold Maintains n/a | Hold | Maintains | n/a | n/a | May 15, 2026 |
| UBS | UBS | Hold Maintains $1.5 | Hold | Maintains | $1.5 | +64.37% | Apr 2, 2026 |
| Evercore ISI | Evercore ISI | Buy Maintains $12 → $7 | Buy | Maintains | $12 → $7 | +667.04% | Apr 1, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.97
from -3.95
EPS Next Year
-1.64
from -1.97
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.22 | -0.28 | ||||||
| Avg | -1.97 | -1.64 | ||||||
| Low | -2.91 | -4.61 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.